If you are selected as an award recipient, you and your institution must agree to the following items, including, but not limited to:

• Exclusive Use of Funding

  The award will be used exclusively to fund the award recipient’s research plan. The itemized budget may not include institutional indirect costs, overhead or general expenses, other than those approved by the Committee.




• Progress Reports

  Submission of research progress and financial accounting reports for review by the Committee are required annually. Funding for the second year is contingent upon Committee Chair approval of the research progress report.




• Publications

  The support of the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension must be acknowledged in any publication or abstracts resulting from research funded by this award.




• Intellectual Property

  The host institution shall retain ownership of any invention resulting from the research funded by this award. The host institution must disclose all inventions to Gilead no later than thirty (30) days following discovery. Prior to offering any license to any invention(s) and resulting patents to third party, the institution must first offer the invention license to Gilead Sciences. The terms of any agreement relating to such rights will be negotiated in good faith by the parties.




• Change of Institution or Discontinuation

  The Research Scholars Program Coordinator must be notified immediately if the award recipient leaves the host institution or discontinues the research funded by the program. In the event award recipient moves to another institution, the award may be transferred at the sole discretion of the Committee. The new host institution must also agree to accept the terms and conditions of the existing award. In the event the host institution or award recipient is unable or desires to discontinue the research before its completion, institution will be required

Award recipients and their institutions will be required to enter into a written grant agreement with Gilead prior to receipt of funding.